ICICI Prudential NIFTY Pharma Index Fund - Direct Plan - Growth

    Compare Fund
    Equity · Index - Sector & ThematicNAV₹20.477 Oct 2026AUM₹157 croreExpense ratio0.52%1Y+20.98%3Y+20.52%5YN/A

    Investment Objective

    The Objective Of The Scheme Is To Invest In Companies Whose Securities Are Included In Nifty Pharma Index And Subject To Tracking Errors, To Endeavor To Achieve The Returns Of…

    Performance vs Benchmark

    FundNAV as of 7 Oct 2026

    Hold this fund?

    See it next to everything else you own: every holding in one place, how it is allocated and how it is really doing.

    Review my portfolio Compare with other funds

    At a glance

    3 year return
    +20.52% a year

    If you had invested

    Period

    Loading NAV history.

    Portfolio

    As of 7 Oct 2026

    Asset class

    • Equity99.9%
    • Others0.1%

    Market cap

    • Large Cap47.8%
    • Mid Cap45.0%
    • Small Cap7.1%
    • Others0.1%

    Key figures

    P/E ratio
    53.0
    Fund size
    ₹157 crore
    Expense ratio
    0.52% a year

    How it compares

    Trailing Returns

    1M3M6MYTD1Y3Y5Y7Y10Y
    This fund-0.92%+3.04%+21.02%+16.57%+20.98%+20.52%N/AN/AN/A

    Calendar Year Returns vs Benchmark

    Comparison with NIFTY Pharma Index

    More detail

    Monthly returns, rolling returns, risk measures and the full NAV history.

    ICICI Prudential NIFTY Pharma Index Fund Direct Plan Growth: summary

    ICICI Prudential NIFTY Pharma Index Fund Direct Plan Growth is an Index - Sector & Thematic equity fund from ICICI Prudential Asset Management Company Limited, launched on 25 Nov 2022. Its benchmark is the NIFTY Pharma Index. The expense ratio is 0.52% a year. It manages ₹157 crore. The NAV was ₹20.47 on 7 Oct 2026.

    Returns and volatility

    PeriodReturnVolatility a year
    Last 1 year+20.98%12.67%
    Last 3 years+20.52% a year15.72%

    Returns over 3 years and longer are compounded annual returns. Volatility is the annualised standard deviation of returns over the same period. Figures as of 7 Oct 2026.

    Calendar year returns against the NIFTY Pharma Index

    From 2017 to 2026, the fund returned more than the NIFTY Pharma Index in 2 of 10 calendar years. The 2026 figure is year to date.

    Year2017201820192020202120222023202420252026 YTD
    CompareReview my portfolio

    Wealth Home

    Track & analyse your Wealth Home

    Connect your mutual funds to see every holding in one place, how it is allocated, and how it is really doing.

    Review my portfolioTalk to an adviser
    QR code to download the RuDo Wealth app

    Scan to connect on the app

    iOS and Android. See your whole portfolio in a minute.

    This fund
    -5.70%
    -7.30%
    -8.65%
    +61.76%
    +10.88%
    -1.68%
    +32.85%
    +38.82%
    -2.59%
    +16.57%
    Benchmark-5.70%-7.30%-8.65%+61.76%+10.88%-10.73%+34.76%+40.03%-2.25%+20.18%

    Investing in this fund from the UAE

    NRIs living in the UAE can generally invest in Indian mutual funds once their KYC is complete, paying from an NRE or NRO bank account.

    Some fund houses do not accept investments from residents of the United States or Canada, or accept them only offline with an extra declaration. If you live in either country, check ICICI Prudential Asset Management Company Limited's current policy before you invest.

    For an equity fund, India taxes gains on units held for 12 months or less at 20%. Gains on units held longer are taxed at 12.5% on the amount above ₹1.25 lakh in a financial year. Cess and any surcharge are added on top. For NRIs, the fund house deducts this tax when you redeem.

    The UAE does not levy personal income tax, and the India UAE tax treaty may affect how your gains are treated. The outcome depends on your tax residence and your facts, so confirm your own position with a tax adviser. Indian tax rates as of October 2026.

    About this data

    Fund data comes from RuDo Wealth fund analytics, with the NAV as of 7 Oct 2026. Calendar year returns are compared with the benchmark that ICICI Prudential Asset Management Company Limited names for this fund. We order funds by published measures such as returns, volatility and years ahead of the benchmark, and we do not label any fund as the best. Method reviewed by Alok Kumar, Chief Executive Officer, RuDo Digital Wealth, October 2026.

    RuDo Wealth is a fee-only cross-border advisory operating through two separate companies. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. The entity permitted to serve you depends on your country of residence.

    This page is general information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.